CME Journal of Clinical Case Reports
ISSN: 3067-7998 | DOI: 10.64030/3067-7998
Sami Al Bitar and Mohamad Tarek Kattan
Background Several risk factors in chronic kidney disease (CKD) patients cause mortality; cardiovascular risk is the most important one. So, new protective treatments have to be added to the management of CKD patients; the most important one is renin angiotensin aldosterone system inhibitors (RAASI), but the latest one is sodium glucose transporter 2 inhibitors (SGLT2i). Here in this study, we tried to approve cardiac and hematologic benefits of Empagliflozine using in end stage renal disease (ESRD) on renal replacement therapy (RRT) patients.
Methods we started Empagliflozin 10 mg for 9 months in 17 hemodialysis patients. Echocardiography and serum hemoglobin to measure cardiac parameters (interventricular septum diameter {IVSD} and ejection fraction{EF%}) and serum hemoglobin (HG) levels were done at baseline and after 9 months. We included diabetic and non-diabetic patients in our study. Patients with urinary anomalies were excluded. Statistical analysis was done to the results by IBM SPSS program to evaluate the benefits.
Results We included 17 participants, 64.7 % of them were male and 35.3% were female. There ages range from 22 years old to 75. Results declared cardiac benefits, as interventricular septum diameter (IVSD) was reduced by mean of 0.08 cm (p.value 0.002), (Std.Deviation(0.088), and increased left ventricular ejection fraction (EF%) by mean of 2.7 % after treatment. (p.value 0.15), (Std.Deviation (7.48), and hematologic benefits, as hemoglobin increased by mean of 0.68 mg/dl (p.value 0.001), (Std.Deviation (0.67), with no important side effects.
Conclusion We concluded that, using empagliflozin in hemodialysis patients, improved cardiac function and increased hemoglobin levels with statistically significance, and may improve prognosis and quality of life.